HJ Science Co., Ltd.

Research HJ Science Co., Ltd. (6132.HK) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

Ticker6132.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Financial periodFY2025
RevenueCNY 12.98M
Revenue growth621.2%
Net income-CNY 135.08M
Free cash flow-CNY 90.95M

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 12.98M	-CNY 135.08M	-CNY 90.95M	n/a	-1.84	CNY 3.72M	CNY 12.65M	CNY 336.20M
FY2024	CNY 1.80M	-CNY 202.32M	-CNY 79.67M	n/a	-2.75	CNY 53.81M	CNY 2.28M	CNY 376.24M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	n/a	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About HJ Science Co., Ltd.

HJ Science Co., Ltd. engages in research and development of new small molecule drugs. The company focuses on metabolic diseases, oncology, and autoimmune disorders. The company's core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the treatment of atopic dermatitis (AD) and acne vulgaris (AV); HJ178, an orally available agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor and intravenous injection intended for the treatment of non-small-cell lung cancer (NSCLC).

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)